Dendritic Cell Therapy
Treatments involving the differentiation of dendritic cells expressing MHC with disease-related antigens and re-introduction of cells into the patient's body induce activation or suppression of antigen-specific immune responses to modulate responses.
Dendritic cells (DC) are known as natural adjuvants of the human immune system, and not only induce early immunity but also perform a central role in immune regulation as the core antigen-presenting cell (APC), and this immunomodulation cell therapy uses differentiated dendritic cells with expressed antigens that are reintroduced into the patient’s body.
Characteristics of Dendritic Cell Therapy
Dendritic cells are antigen-presenting cells that perform antigen presentation to T cells, and are present in dendritic form in the intercellular spaces of various tissues including lymph nodes, spleen, thymus, skin, or other tissues.
Dendritic cells absorb antigens intracellularly and present various antigen samples to T cells along with major histocompatibility complex (MHC) class I or class II molecules, which play an important role in T cell activation. Also, dendritic cells differentiate into various levels of maturity according to their type and surrounding environmental signals to exist as immature, semi-mature, or mature dendritic cells, and semi-mature dendritic cells are known to be related to immune tolerance, which is different from mature ones.
Pharos Vaccine is performing clinical research on the maturation conditions of immune-tolerant dendritic cells, type and characteristics of expressed antigens, administration dose, administration route, and administration schedules, for effective use against autoimmune diseases.
Isolation & Activation
Pharos Vaccine is applying these characteristics of dendritic cells to development of tolerogenic dendritic cells (tDC) to induce immune tolerance with an aim of treating autoimmune diseases such as rheumatoid arthritis and myocarditis. These cells are designed to move to nearby lymph nodes when injected into the body and react with naïve T cells to induce specific regulatory T cells, and are fundamental treatments with significantly lower rates of adverse events.